|
Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?
Answer: TCH + lapatinib
In the neoadjuvant setting, I generally treat locally advanced, ER-negative, HER2-positive breast cancer in a patient who desires breast conservation with TCH/lapatinib. If you consider the data, the pathologic complete response (pCR) rate for dual HER2-targeted therapies appears to be higher. Frequently, I can obtain coverage for lapatinib in combination with TCH for patients in this setting.
Answer: AC
![]() It depends on the definition of locally advanced disease. If it’s T4 or N2 disease, I believe it’s reasonable to treat with a dual HER2-targeting combination with anthracycline/taxane. If the disease is not inflammatory, I would treat with AC For most patients with HER2-positive breast cancer, I tend to recommend the chemotherapy regimens that have been proven. My interpretation of the BCIRG 006 trial is that TCH is a perfectly reasonable regimen. It was numerically inferior to an anthracycline regimen but was associated with fewer cardiac toxicities. The data suggest that patients with HER2-positive breast cancer benefit from treatment with anthracyclines. Hence, I tend to use the AC
Answer: AC
![]() I would usually administer AC
Answer: AC
![]() In the neoadjuvant setting, for a patient such as this I generally opt for AC
Answer: AC
![]() I generally approach this situation in the same way that I would in the adjuvant setting. I administer AC
Answer: AC
![]() Our neoadjuvant regimens are identical to the adjuvant regimens. For a patient with locally advanced, HER2-positive breast cancer who desired breast conservation, I would recommend AC
Answer: FEC75
![]() In this situation, I used to administer the Buzdar regimen of FEC75 with trastuzumab, followed by weekly paclitaxel/trastuzumab. The results of the ACOSOG-Z1041 trial, presented at ASCO 2013, showed that the concurrent administration of trastuzumab with FEC75 was not important, so I will stop that going forward. Since FEC75/trastuzumab is not superior to FEC75 followed by paclitaxel/trastuzumab, it raises an interesting question about the option of administering dose-dense AC → TH. However, the prevailing argument is that FEC75 with trastuzumab is safer for the heart than AC. Also, the randomized TRYPHAENA trial showed similar pCR rates of about 60% to 70% when patients were assigned preoperatively to TCH with pertuzumab versus FEC followed by taxane/trastuzumab/pertuzumab. TCH/pertuzumab may become the standard toward the end of the year.
Answer: Pac + trastuzumab
![]() We enroll almost all of our patients on the I-SPY 2 neoadjuvant trial investigating the benefit of adding different HER2-directed therapies or novel agents to standard neoadjuvant chemotherapy. For a patient who is not willing to be enrolled on the I-SPY 2 trial, I would opt for weekly paclitaxel and trastuzumab for 12 cycles followed by 4 cycles of AC before surgery. If the patient is elderly and can’t tolerate or refuses an anthracycline-based regimen, I would recommend TCH. |